FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, which can be used to treat and/or prevent cancer, tumour or metastatic disease, at least partially related with Del19 EGFR mutation, L858R EGFR mutation, L858R/C797S EGFR double mutation or Del19/C797S EGFR double mutation. In formula (I), each of X1 and X2 independently represents N or CR7; Z is CH; R1 is halogen or C1-10 alkoxy, wherein said C1-10 alkoxy is optionally substituted with one or more substitutes selected from halogen; R2 is selected from the group consisting of halogen, C1-10 alkyl, C3-12 cycloalkyl and 5-10 membered heteroaryl, wherein said groups are independently optionally substituted with one or more substitutes selected from C1-10 alkyl; R3 and R4 together with the nitrogen atom to which they are directly attached form 4-12-membered heterocyclyl, wherein said group is optionally substituted with one or more substitutes selected from C1-10 alkyl and 3-12-membered heterocyclyl, wherein said groups are optionally substituted with one or more substitutes selected from C1-10 alkyl; each of R5 is independently selected from hydrogen and halogen; R6 is a hydrogen; each R7 is a hydrogen; m is equal to 0, 1, 2, 3, 4 or 5; unless specified specifically, the heterocyclyl heteroatom in the above substituents is 1 or 2 nitrogen or oxygen, the heteroaryl heteroatom in the above substituents is 1 or 2 nitrogen.
EFFECT: invention also relates to a method of producing a compound of formula (I), a pharmaceutical composition containing it and versions of its use for treating and/or preventing diseases at least partially related to Del19 EGFR mutation, L858R EGFR mutation, L858R/C797S EGFR double mutation or Del19/C797S EGFR double mutation.
17 cl, 1 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND AIMED AT PROTEIN AND DEGRADATION THEREOF, AND METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2829459C1 |
| FGFR AND ITS MUTATION INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2811207C1 |
| CLASS OF CONDENSED RING COMPOUNDS AND THEIR PRODUCTION AND USE | 2021 |
|
RU2831125C1 |
| INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
| PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
| INHIBITORS, A METHOD OF THEIR PREPARATION AND USE | 2019 |
|
RU2806033C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
| TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DESTROYERS | 2017 |
|
RU2797244C2 |
| NEUROKININ-1 ANTAGONIST | 2020 |
|
RU2827715C2 |
